MICI-Covid-19
SARS-CoV-2 Infection in Patients From Two Tertiary Inflammatory Bowel Disease (IBD) Centres: Frequency of Suspected and Confirmed Infections, Severity and Outcome Management
Sponsor study identifier
observational
700
1 country
1
Study Start
July 7, 2020
Actual (reported)Primary Completion
January 7, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 7, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Most of the inflammatory bowel disease (IBD: Crohn's disease and ulcerative colitis) in a tertiary expert Centre are on immunosuppressive and/or biological therapy. Theoretically, these treatments may increase patients' risk of infection, in particular viral infection. Therefore, the current SARS-Cov-2 pandemia, with its unprecedent worldwide morbidity and mortality, may have a negative impact on IBD patients' clinical course. Identifying an increased risk in this particular patients' population as well as the risk/protective factors is of outstanding importance, in order to adapt their treatment and surveillance. As a consequence, our aims were (i) to measure retrospectively the risk of SARS-CoV-2 (proven by biological testing or suspected due to record of potential clinical symptoms of COVID-19 infection) in this patients' cohort (principal objective), (ii) to identify risk or protective factors for SARS-CoV-2 infection in IBD, and (iii) to analyze the outcome of patients in case of suspected or confirmed COVID-19. The results of this study may be important to adjust our surveillance and therapeutic strategy in these patients, in particular if high virus circulation will occur in the future.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 7, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 7, 2020
Actual (reported)July 23, 2020
Actual (reported)July 30, 2020
Actual (reported)January 7, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 7, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Retrospective analysis of severity and specific needs in case of SARS-CoV-2 infection in IBD patients
Files analysed retrospectily from March 1st, 2020 to July 31, 2020 will be examined
IBD patient (Crohn's disease, ulcerative colitis, indeterminate colitis) over the age of 18 years
Service Hépato-Gastroentérologie et Assistance Nutritive Hôpitaux Univesitaires de Strasbourg
Strasbourg, 67091, France
First Submitted
July 23, 2020
First Posted
July 30, 2020
Study Start
July 7, 2020
Actual (reported)Primary Completion
January 7, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Urinary PGE-MUM (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as Inflammatory Marker in Chronic Inflammatory Bowel Disease
Contact the study team to confirm eligibility.
Study Completion
January 7, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
July 30, 2020
Record last verified: 2020-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: